Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Arrowhead Pharmaceuticals Inc (Arrowhead) is a biotech company that develops and commercializes gene silencing therapeutics. The company’s pipeline products include Plozasiran (ARO-APOC3) which targets hypertriglyceridemia, familial chylomicronemia syndrome and dyslipidemia; Zodasiran (ARO-ANG3) treats dyslipidemia and homozygous familial hypercholesterolemia; Olpasiran for cardiovascular disease; ARO-ALK7 and ARO-INHBE targets obesity; GSK4532990 and ARO-PNPLA3 targets metabolic dysfunction–associated steatohepatitis; ARO-ATXN2 for spinocerebellar ataxia 2; ARO-RAGE targets inflammatory pulmonary diseases; aro-MMP7 for idiopathic pulmonary fibrosis; among others. It utilizes RNA chemistries and TRiM platform to target and silence disease-causing genes. Arrowhead is headquartered in Pasadena, California, the US.
Headquarters
United States of America
Address
Suite 700, 177 East Colorado Boulevard, Pasadena, California, 91105
Website
www.arrowheadpharma.com
Telephone
1 626 3043400
No of Employees
711
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ARWR (NASD)
Revenue (2024)
$829.4M
23258.2%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
99.7%
(2024 vs 2023)
Market Cap*
$10.2B
Net Profit Margin (2024)
XYZ
100.0%
(2024 vs 2023)
* As of and is in US$
Arrowhead Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | TRiM - Targeted RNAi Molecule |
| Plozasiran (ARO-APOC3): | |
| Hypertriglyceridemia | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In December, the company received breakthrough therapy designation from the U.S. Food and Drug Administration for investigational plozasiran as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia. |
| 2025 | Regulatory Approval | In November, the company secured approval from the U.S. Food and Drug Administration for REDEMPLO (plozasiran), a small interfering RNA (siRNA) medicine. |
| 2025 | Others | In October, the company submitted a request for approval to initiate a Phase 1/2a clinical trial of ARO-DIMER-PA for the treatment of atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. |
Competitor Comparison
| Key Parameters | Arrowhead Pharmaceuticals Inc | Blueprint Medicines Corp | BridgeBio Pharma Inc | Viridian Therapeutics Inc | aTyr Pharma Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Pasadena | Cambridge | Palo Alto | Waltham | San Diego |
| State/Province | California | Massachusetts | California | Massachusetts | California |
| No. of Employees | 711 | 682 | 725 | 252 | 56 |
| Entity Type | Public | Private | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Christopher Anzalone, PhD | President; Chief Executive Officer; Chairman | Executive Board | 2007 | 55 |
| Daniel Apel | Chief Financial Officer | Senior Management | 2025 | - |
| Patrick O’Brien | General Counsel; Chief Operating Officer | Senior Management | 2022 | 61 |
| James Hamilton, MD | Chief Medical Officer; Chief - Discovery and Translational Medicine | Senior Management | 2025 | 47 |
| Andy Davis | Head - Metabolic Franchise; Senior Vice President - Cardiovascular | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer